Related Experiment Videos
Protein C assays in uremia.
P J Sørensen1, F Knudsen, A H Nielsen
1Department of Medicine, Nephrology C and Clinical Chemistry, Aalborg Hospital, Denmark.
Thrombosis Research
|May 15, 1989
Summary
Patients with uremia show significantly reduced protein C anticoagulant activity, which partially recovers after hemodialysis. This defect in protein C may increase the risk of blood clots.
Area of Science:
- Biochemistry
- Hematology
- Nephrology
Background:
- Uremia, a condition of kidney failure, is associated with an increased risk of thromboembolic complications.
- Protein C is a crucial anticoagulant vitamin K-dependent protein that regulates blood coagulation.
Purpose of the Study:
- To investigate the status of protein C anticoagulant activity, amidolytic activity, and antigen levels in patients with terminal uremia.
- To explore the potential causes of defective protein C in uremia and its relationship with hemodialysis.
Main Methods:
- Protein C levels were measured using three assays: anticoagulant activity, amidolytic activity, and antigen level.
- Comparisons were made between 42 uremic patients and 20 healthy controls.
- Factor II and X activities, prothrombin levels, and BaCl2 precipitation were also assessed.
Main Results:
- Protein C anticoagulant activity was significantly decreased in uremic patients but showed partial normalization post-hemodialysis.
- Amidolytic activity and antigen levels of protein C remained normal in uremic patients and were unaffected by dialysis.
- No evidence of defective carboxylation was found, and in vitro addition of uremic toxins did not impair protein C activity.
Conclusions:
- Uremia is associated with a defect in protein C anticoagulant function, distinct from its amidolytic activity or antigen levels.
- The exact cause of this defect remains unknown but may contribute to the heightened risk of thrombosis in uremic patients.